NASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis $26.28 -0.15 (-0.57%) (As of 11:09 AM ET) Add Compare Share Share Today's Range$25.95▼$26.4150-Day Range$17.98▼$26.6352-Week Range$14.12▼$27.88Volume24,577 shsAverage Volume422,621 shsMarket Capitalization$1.86 billionP/E Ratio238.93Dividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside21.1% Upside$32.00 Price TargetShort InterestBearish6.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 6 Articles This WeekInsider TradingSelling Shares$4.67 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.05) to $0.54 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 starsMedical Sector673rd out of 924 stocksPharmaceutical Preparations Industry310th out of 426 stocks 2.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiniksa Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.36% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently increased by 14.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.9 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest8 people have searched for KNSA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,671,729.00 in company stock.Percentage Held by Insiders54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.05) to $0.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 240.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 240.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.87.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesJuly 26, 2024 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells 22,000 Shares of StockJuly 26, 2024 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 136,124 Shares of StockAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 20 at 3:40 AM | finance.yahoo.comKNSA Sep 2024 25.000 put (KNSA240920P00025000)August 19 at 3:43 PM | theglobeandmail.com3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft LandingJuly 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call TranscriptJuly 24, 2024 | markets.businessinsider.comBuy Rating for Kiniksa Pharmaceuticals Amidst Strong Arcalyst Performance and Promising Clinical TrialsJuly 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 BeatAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.July 24, 2024 | msn.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2024 Earnings Call TranscriptJuly 23, 2024 | marketwatch.comKiniksa Pharma Shares Rise 27% After 2Q Earnings, Arcalyst Sales Guidance IncreaseJuly 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals International, plc 2024 Q2 - Results - Earnings Call PresentationJuly 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio ExecutionJuly 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024July 9, 2024 | globenewswire.comKiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's DiseaseJune 17, 2024 | globenewswire.comKiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis InitiativeJune 4, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 10, 2024 | markets.businessinsider.comMarket Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry IndicatorsSee More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/23/2024Today8/22/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+21.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio240.29 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins-3.10% Pretax Margin-5.32% Return on Equity-7.79% Return on Assets-6.43% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.16 Sales & Book Value Annual Sales$338.93 million Price / Sales5.53 Cash FlowN/A Price / Cash FlowN/A Book Value$6.11 per share Price / Book4.33Miscellaneous Outstanding Shares70,940,000Free Float32,228,000Market Cap$1.87 billion OptionableOptionable Beta0.38 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.57MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $733.29kDr. John F. Paolini FACC (Age 59)M.D., Ph.D., Senior VP & Chief Medical Officer Comp: $855.79kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Mr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary More ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNOcular TherapeutixNASDAQ:OCULInnovivaNASDAQ:INVAArcutis BiotherapeuticsNASDAQ:ARQTPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCSold 6,704 shares on 8/16/2024Ownership: 0.868%Algert Global LLCBought 8,156 shares on 8/16/2024Ownership: 0.026%AQR Capital Management LLCSold 33,328 shares on 8/15/2024Ownership: 0.178%Lion Point Capital LPSold 26,000 shares on 8/15/2024Ownership: 0.148%Lynx1 Capital Management LPBought 9,500 shares on 8/15/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals' stock was trading at $17.54 at the start of the year. Since then, KNSA shares have increased by 50.7% and is now trading at $26.43. View the best growth stocks for 2024 here. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Tuesday, July, 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. The company's revenue was up 51.5% on a year-over-year basis. What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' top institutional investors include Rubric Capital Management LP (3.41%), Dimensional Fund Advisors LP (0.94%), Millennium Management LLC (0.88%) and Driehaus Capital Management LLC (0.87%). Insiders that own company stock include Sanj K Patel, John F Paolini, Mark Ragosa, Michael R Megna and Barry D Quart. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and AbbVie (ABBV). This page (NASDAQ:KNSA) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
